CONTEXT: Commercial announcement from Biodesix and Datavant to enhance their current lung cancer specific RWD biobank. It is hoped that the enhanced datasets will help pin future NSCLC treatments.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 6
1. “Real-world patient level data not only helps physicians improve treatment decisions, it also informs researchers and biopharma companies on key decisions throughout the product development cycle, from early discovery to late stage clinical development, including such uses as meaningful RWE synthetic control arms.”
2. “BOULDER, Colorado and SAN FRANCISCO, June 04, 2021 (GLOBE NEWSWIRE) — Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, the leader in helping healthcare organizations safely connect their data.”
3. “Through this partnership, Biodesix will anonymize the lung cancer portion of their expansive sample and data biobank using Datavant’s proprietary tokenization process and connect it to multiple real-world data sets while compliantly and securely protecting patient privacy.”
4. “”We believe connecting the rich Biodesix data to other sources of real-world data will advance the diagnoses, treatment and research in lung cancer.””
5. “The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment.”